Advertisement

Peritonectomy as a Treatment Modality for Patients with Peritoneal Dissemination from Gastric Cancer

  • Yutaka Yonemura
  • Takashi Fujimura
  • Sachio Fushida
  • Hideto Fujita
  • Etsurou Bando
  • Keizo Taniguchi
  • Gen-Ichi Nishimura
  • Kouichi Miwa
  • Shigekazu Ohyama
  • Kazuo Sugiyama
  • Takuma Sasaki
  • Yoshio Endo

Abstract

Gastric cancer is still a leading cause of death in Japan, and the most frequent cause of death from this disease is peritoneal dissemination. Intraperitoneal chemotherapy has been performed to treat peritoneal dissemination, but the treatment results remain poor [1, 2, 3, 4, 5]. The reasons for treatment failure are believed to be as follows: (1) the penetration distance of the intraperitoneally (i.p.) injected drugs into the submesothelial tissue is limited to a 2–3 mm [3,6]; (2) intraperitoneally injected drugs usually distribute unevenly because of the anatomical complexity of the peritoneal cavity [7]; and (3) complete elimination of peritoneal carcinomatosis with chemotherapy may fail in nodules larger than 3 mm because of the development of multidrug-resistant clones by mutation [8]. For these reasons the treatment results for patients with peritoneal carcinomatosis remain poor. Consequently, thorough surgical resection of peritoneal dissemination is considered to be the only option for cure, although peritoneal dissemination cannot be completely eliminated with the usual surgical techniques because “invisible” cancer cells have already spread over the peritoneal surface outside the surgical field.

Keywords

Gastric Cancer Peritoneal Carcinomatosis Peritoneal Dissemination Intraperitoneal Chemotherapy Complete Cytoreduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, Taniguchi H, Kitamura K, Noguchi A, Seiki K, Sakakura C (1992) Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 339:629–631PubMedCrossRefGoogle Scholar
  2. 2.
    Koga S, Izumi A, Maeta M, Shimizu N, Osaki Y, Kanayama H (1983) The effects of total-body hyperthermia combined with anticancer drugs on immunity in advanced cancer patients. Cancer 52:1173–1177PubMedCrossRefGoogle Scholar
  3. 3.
    Markman M (1991) Intraperitoneal chemotherapy. Semin Oncol 18:248–254PubMedGoogle Scholar
  4. 4.
    Brenner DE (1986) Intraperitoneal chemotherapy: a review. J Clin Oncol 4:1135–1147PubMedGoogle Scholar
  5. 5.
    Nakajima T (1994) Tabular analysis of 10000 cases of gastric cancer. Jpn J Cancer Chemother 1813–1897Google Scholar
  6. 6.
    Los G, Mutsaers PHA, van der Vijgh WJF, Badlew GS, de Graaf PW, McVie JG (1989) Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemoterapy: a comparison with systemic chemoterapy. Cancer Res 49:3380–3384PubMedGoogle Scholar
  7. 7.
    Averbach AM, Sugarbaker PH (1996) Methodologic considerations in treatment using intraperitoneal chemotherapy. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwar Academic, Boston, pp 289–309CrossRefGoogle Scholar
  8. 8.
    Yonemura Y (1996) Mechanisms of drug resistance in gastric cancer. In: Yonemura Y (ed) Contemporary approaches toward cure of gastric cancer. Maeda Shoten, Kanazawa, pp 163–176Google Scholar
  9. 9.
    Sugarbaker PH (1996) Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwar Academic, Boston, pp 75–87CrossRefGoogle Scholar
  10. 10.
    Yonemura Y (1996) Surgical techniques for subtotal peritonectomy. In: Yonemura Y (ed) Contemporary approaches toward cure of gastric cancer. Maeda Shoten, Kanazawa, pp 163–176Google Scholar
  11. 11.
    Yonemura Y, Fujimura T, Nishimura G, Falla R, Sawa T, Katayama K, Tsugawa K, Fushida S, Miyazaki I, Tanaka M, Endou Y, Sasaki T (1996) Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 119:437–444PubMedCrossRefGoogle Scholar
  12. 12.
    Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, Ohoyama S, Takashima T, Kimura H, Kamata T, Fujimura T, Sugiyama K, Shima K, Miyazaki I (1993) Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 17:256–263PubMedCrossRefGoogle Scholar
  13. 13.
    Yonemura Y (1996) D2-gastrectomy. In: Yonemura Y (ed) Contemporary approaches toward cure of gastric cancer. Maeda Shoten, Kanazawa, pp 139–146Google Scholar
  14. 14.
    Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwar Academic, Boston, pp 359–374CrossRefGoogle Scholar
  15. 15.
    Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stall M, Leans L, Meyer J, Siewert JR, Greerlings H, Kohne-Wompner CH, Harstrick A, Schmoll HJ (1990) New development in the treatment of gastric cancer. Semin Oncol 17:61–70PubMedGoogle Scholar
  16. 16.
    Sugarbaker PH, Stuart A, Vidal-Jove J, Pessagno AM, Debruijin EA (1994) Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwar Academic, Boston, pp 41–51Google Scholar
  17. 17.
    Jain RK (1994) Barriers to drug delivery in solid tumor. Sci Am 7:42–49Google Scholar
  18. 18.
    Hiratsuka M, Ogawa A, Oohigashi A, Kameyama M, Sasaki H, Ishikawa O, Kabuto T, Fukuda I, Furukawa H, Iomaoka M, Koyama H, Iwanaga T (1988) Dosage and its safety on intraperitoneal high dose mitomycin C administration as postoperative adjuvant therapy for gastric cancer. J Jpn Soc Cancer Ther 23:1574–1579Google Scholar
  19. 19.
    Giovanella BC (1973) Selective lethal effect of supranormal temperatures on mouse sarcoma cells. Cancer Res 33:2568–2578PubMedGoogle Scholar
  20. 20.
    Los G, van Vugt MJH, Pinedo HM (1994) Response of peritoneal solid tumors after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 69:235–241PubMedCrossRefGoogle Scholar
  21. 21.
    Hettinga JVE, Lemstra W, Meijer C, Dam WA, Uges WA, Konings AWT, De Vries EGE, Kampinga HH (1997) Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and-resistant tumor cells. Br J Cancer 75:1735–1743PubMedCrossRefGoogle Scholar
  22. 22.
    Skipper HE (1978) Reasons for success and failure of treatment of murine leukemia with the drugs now employed treating human leukemias. In: Cancer chemotherapy, vol 1. University Microfilms, Ann Arbor, MIGoogle Scholar
  23. 23.
    Shidou A, Konayashi H, Yamamoto K, Kobayashi T, Fujimura T, Yonemura Y (1997) Peritoneal damage after continuous hyperthermic peritoneal perfusion/thermoregulation. Annal New York Acad Sci 813:610–613CrossRefGoogle Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Yutaka Yonemura
    • 1
  • Takashi Fujimura
    • 1
  • Sachio Fushida
    • 1
  • Hideto Fujita
    • 1
  • Etsurou Bando
    • 1
  • Keizo Taniguchi
    • 1
  • Gen-Ichi Nishimura
    • 1
  • Kouichi Miwa
    • 1
  • Shigekazu Ohyama
    • 2
  • Kazuo Sugiyama
    • 3
  • Takuma Sasaki
    • 4
  • Yoshio Endo
    • 4
  1. 1.Department of Surgery II, School of MedicineKanazawa UniversityKanazawaJapan
  2. 2.Cancer Institute HospitalTokyoJapan
  3. 3.Department of VirologyNational Cancer CenterTokyoJapan
  4. 4.Department of Experimental Therapentics, School of MedicineKanazawa UniversityKanazawaJapan

Personalised recommendations